# US 2003/0216476 A1 · Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216476 A1
- Document ID: US20030216476A1
- Status: Published application
- Kind: A1
- Application number: 10/429,810
- Filed: 2003-05-05
- Published: 2003-11-20
- Earliest claimed: 2002-05-18
- Assignees: Aventis Pharma Deutshchland GmbH
- Inventors: Heinz-Werner Kleemann
- Web page: https://patentgrep.com/patent/US20030216476A1

## CPC

- C07C 381/00: Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 35/00: Antineoplastic agents
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pentafluorosulfanylbenzoylguanidines of the formula I and II 1 in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.

## Claims

### Claim 1

A pentafluorosulfanylbenzoylguanidine compound of the formula I or II
11
in which
R1 is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, CN, NR10R11, —Op—(CH2)n—(CF2)o—CF3 or —(SOm)q—(CH2)r—(CF2)s—CF3;
R10 and R11
are, independently of one another, hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or —CH2—CF3;
m is zero, 1 or 2
n, o, p, q, r and s
are, independently of one another, zero or 1;
R2 is hydrogen, F, Cl, Br, I, —CN, —SO2CH3, —(SOh)z—(CH2)k—(CF2)l—CF3, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms,
in which 1, 2, 3 or 4 hydrogen atoms may be replaced by fluorine atoms;
h is zero, 1 or 2;
z is zero or 1;
k is zero, 1, 2, 3 or 4;
l is zero or 1; or
R2 is —(CH2)t-phenyl or —O-phenyl,
in which each phenyl is unsubstituted or substituted by 1, 2 or 3 radicals selected from the group consisting of F, Cl, Br, I, —Ou—(CH2)v—CF3, alkoxy having 1, 2, 3 or 4 carbon atoms, alkyl having 1, 2, 3 or 4 carbon atoms and —SO2CH3;
t is zero, 1, 2, 3 or 4;
u is zero or 1;
v is zero, 1, 2 or 3; or
R2 is —(CH2)w-heteroaryl,
in which heteroaryl is unsubstituted or substituted by 1, 2 or 3 radicals selected from the group consisting of F, Cl, Br, I, —Ox—(CH2)y—CF3, alkoxy having 1, 2, 3 or 4 carbon atoms and alkyl having 1, 2, 3 or 4 carbon atoms, —SO2CH3;
w is zero, 1, 2, 3 or 4;
x is zero or 1;
y is zero, 1, 2 or 3;
R3 and R4
are, independently of one another, hydrogen or F;
and the pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

A compound of the formula I or II as claimed in claim 1, in which the meanings are:
R1 hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, F, Cl, NR10R11, —O—CH2—CF3 or SOm(CH2)r—CF3;
R10 and R11
independently of one another hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or —CH2—CF3;
m zero, 1 or 2;
r zero or 1;
R2 hydrogen, F, Cl, —SO2CH3, —(SOh)z—(CH2)k—CF3, alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms,
in which 1, 2, 3 or 4 hydrogen atoms may be replaced by fluorine atoms;
h zero, 1 or 2;
z zero or 1;
k zero, 1, 2, 3 or 4; or
R2 phenyl or —O-phenyl,
which is unsubstituted or substituted by 1 or 2 radicals selected from the group consisting of F, Cl, —Ou—(CH2)v—CF3, methoxy, ethoxy, alkyl having 1, 2, 3 or 4 carbon atoms and —SO2CH3;
u zero or 1;
v zero, 1, 2 or 3; or
R2 heteroaryl,
which is unsubstituted or substituted by 1 or 2 radicals selected from the group consisting of F, Cl, —Ox—(CH2)y—CF3, methoxy, ethoxy, alkyl having 1, 2, 3 or 4 carbon atoms and —SO2CH3;
x zero or 1;
y zero, 1, 2 or 3;
R3 and R4
independently of one another hydrogen or F;
and the pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 2)

A compound of the formula I or II as claimed in claim 2, in which the meanings are:
R1 hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, methoxy, ethoxy, F, Cl, NR10R11, —O—CH2—CF3 or —SOm—(CH2)r—CF3;
R10 and R11
independently of one another hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or —CH2—CF3;
m zero, 1 or 2;
r zero or 1;
R2 hydrogen, F, Cl, —SO2CH3, —(SOh)z—(CH2)k—CF3, alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms,
in which 1, 2, 3 or 4 hydrogen atoms may be replaced by fluorine atoms;
zero or 2;
z zero or 1;
k zero or 1; or
R2 phenyl or —O-phenyl,
which is unsubstituted or substituted by 1 or 2 radicals selected from the group consisting of F, Cl, —O—(CH2)v—CF3, methoxy, ethoxy, alkyl having 1, 2, 3 or 4 carbon atoms and —SO2CH3;
v zero, 1, 2 or 3; or
R2 heteroaryl,
which is unsubstituted or substituted by 1 or 2 radicals selected from the group consisting of F, Cl, —O—(CH2)y—CF3, methoxy, ethoxy, alkyl having 1, 2, 3 or 4 carbon atoms and —SO2CH3;
y zero, 1, 2 or 3;
R3 and R4
hydrogen;
and the pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

A process for preparing a compound as claimed in claim 1 of the formula I or II, and the pharmaceutically acceptable salts thereof, which comprises reacting a compound of the formula III or IV, respectively,
12
in which R1 to R4 have the meanings stated in claim 1, and L is a leaving group which can readily undergo nucleophilic substitution, with guanidine.

### Claim 5 (depends on 1)

A method for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events, for the treatment or prophylaxis of arrhythmias, of life-threatening cardiac ventricular fibrillation, of myocardial infarction, of angina pectoris, for the treatment or prophylaxis of ischemic states of the heart, of ischemic states of the peripheral and central nervous system or of stroke or of ischemic states of peripheral organs and tissues, for the treatment or prophylaxis of states of shock, of diseases in which cellular proliferation represents a primary or secondary cause, of cancer, of metastasis, of prostate hypertrophy and of prostate hyperplasia, of atherosclerosis or of disturbances of lipid metabolism, of high blood pressure, of disorders of the central nervous system, for the treatment or prophylaxis of non-insulin-dependent diabetes mellitus (NIDDM) or late damage from diabetes, of thromboses, of disorders resulting from endothelial dysfunction, of intermittent claudication, for the treatment or prophylaxis of fibrotic disorders of internal organs, fibrotic disorders of the liver, fibrotic disorders of the kidney, fibrotic disorders of vessels and fibrotic disorders of the heart, for the treatment or prophylaxis of heart failure or of congestive heart failure, of acute or chronic inflammatory disorders, of disorders caused by protozoa, of malaria and of coccidiosis in poultry, for preserving and storing transplants for surgical procedures, for preventing age-related tissue change, for inhibiting aging, for prolonging life, for the treatment and reduction of the cardiotoxic effects in thyrotoxicosis, or for producing a diagnostic aid, said method comprising the use or administration of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

A method for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events, for the treatment or prophylaxis of arrhythmias, of life-threatening cardiac ventricular fibrillation, of myocardial infarction, of angina pectoris, for the treatment or prophylaxis of ischemic states of the heart, of ischemic states of the peripheral and central nervous system or of stroke or of ischemic states of peripheral organs and tissues, for the treatment or prophylaxis of states of shock, of diseases in which cellular proliferation represents a primary or secondary cause, of cancer, of metastasis, of prostate hypertrophy and of prostate hyperplasia, of atherosclerosis or of disturbances of lipid metabolism, of high blood pressure, of disorders of the central nervous system, for the treatment or prophylaxis of non-insulin-dependent diabetes mellitus (NIDDM) or late damage from diabetes, of thromboses, of disorders resulting from endothelial dysfunction, of intermittent claudication, for the treatment or prophylaxis of fibrotic disorders of internal organs, fibrotic disorders of the liver, fibrotic disorders of the kidney, fibrotic disorders of vessels and fibrotic disorders of the heart, for the treatment or prophylaxis of heart failure or of congestive heart failure, of acute or chronic inflammatory disorders, of disorders caused by protozoa, of malaria and of coccidiosis in poultry, for preserving and storing transplants for surgical procedures, for preventing age-related tissue change, for inhibiting aging, for prolonging life, for the treatment and reduction of the cardiotoxic effects in thyrotoxicosis, or for producing a diagnostic aid, said method comprising the use or administration of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, in combination with other medicaments or active ingredients.

### Claim 7 (depends on 1)

A method for reducing the cardiotoxic and cytotoxic properties of a medicament or active ingredient having cardiotoxic and cytotoxic properties comprising combining a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, with such medicament or active ingredient.

### Claim 8 (depends on 1)

A method for the treatment of or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events comprising the administration of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, alone or in combination with other medicaments or active ingredients.

### Claim 9 (depends on 1)

A method for the treatment of life-threatening cardiac ventricular fibrillation comprising the administration of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, alone or in combination with other medicaments or active ingredients.

### Claim 10 (depends on 1)

A method for the treatment or prophylaxis of metastasis comprising the administration of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, alone or in combination with other medicaments or active ingredients.

### Claim 11 (depends on 1)

A method for the treatment or prophylaxis of fibrotic disorders of the heart, of heart failure or of congestive heart failure comprising the administration of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, alone or in combination with other medicaments or active ingredients.

### Claim 12 (depends on 1)

A medicine for human, veterinary or phytoprotective use comprising an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable carriers and additives.

### Claim 13 (depends on 1)

A medicine for human, veterinary or phytoprotective use comprising an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable carriers and additives, and further in combination with other pharmacologically active ingredients or medicaments.

### Claim 14

A compound of the formula V
13
with R5 equal to hydrogen or (C1-C4)-alkyl.
